The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Cardiol Therapeutics. This could potentially lead to an increase in the stock's price in the short term. The maintained price target of $3 also suggests that the analyst believes the stock is currently undervalued.